Table 1.
Summary of some selected prospective stereotactic body radiotherapy series.
| Study | Design | Case and lesions | Dose (Gy) /fractions | Follow-up | Local control | Overall survival | PFS | Toxicity |
|---|---|---|---|---|---|---|---|---|
| Hoyer M 2006 | Phase II | 64 patients 141 lesions |
45/3 | 4.3 (0.2-6.3) years | 1-year: 86% | 1-year: 67% 5-year: 13% |
Median: 6.5 Mo 2-year: 19% |
Grade 2: 48% |
| Kavanagh B 2006 | Phase I-II | 21 patients | 60/3 | 19 (6-29) Mo | Median: 18 Mo 1-year: 93% |
NA | NA | Grade 3: 1 |
| Rusthoven K 2009 | Phase I/II | 47 patients 63 lesions |
36-60/3 | 16 (6-54) Mo | 1-year: 95% 2-year: 92% |
Median: 20.5 Mo 2-year: 30% |
NA | Grade 3: 2% |
| Lee M 2009 |
Phase I | 68 patients | 54-60/6 | 10.8 Mo | 1-year: 71% | Median: 17.6 Mo 1-year: 63% |
NA | Grade 3: 10% |
| Rule W 2011 |
Phase I | 27 patients 37 lesions |
30-60/5 | 20 (4-53) Mo | 1-year: 72% | Median: 37 Mo 2-year: 57.6% |
NA | Grade 3: 1 |
| Scorsetti M 2012 | Phase II | 61 patients 76 lesions |
75/3 | 6.1 years | 1-year: 95% | Median: 27.6 Mo 1-year: 85% 5-year: 18% |
Median: 12 Mo | No grade 3 |
| Hong T 2017 | Phase II | 89 patients 143 lesions |
40 GyE/5 |
30.1 (14.7-53.8) Mo | 1-year: 71.9% 3-year: 61.2% |
1-year: 66.3% 2-year: 35.9% 3-year: 20.8% |
NA | No Grade ≥ 3 |
| Folkert M 2021 | Phase I | 33 patients 39 lesions |
35-40/1 | 25.9 Mo | 4-year: 96.6% | 2-year: 82% | NA | No Grade ≥ 3 |
Abbreviations: Mo, months; NA, not available; PFS, progression-free survival.